Cargando…

Health economic evaluation of nation-wide screening programmes for atrial fibrillation in the Netherlands

AIMS: Screening for atrial fibrillation (AF) is recommended by the European Society of Cardiology guidelines to prevent strokes. Cost-effectiveness analyses of different screening programmes for AF are difficult to compare because of varying settings and models used. We compared the impact and cost-...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Hulst, Marinus, Tieleman, Robert G, Zwart, Lennaert A R, Pomp, Marc, Jacobs, Maartje S, Meeder, Joan G, van Ofwegen-Hanekamp, Clara E E, Hollander, Monika, Smits, Paul, Hemels, Martin E W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284264/ https://www.ncbi.nlm.nih.gov/pubmed/35881482 http://dx.doi.org/10.1093/ehjqcco/qcac042

Ejemplares similares

Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation
por: Jacobs, Maartje S., et al.
Publicado: (2017)

Incidence, treatment and mortality of new-onset atrial fibrillation patients at the intensive care unit
por: Jacobs, Maartje S, et al.
Publicado: (2020)

Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry
por: Pisters, R., et al.
Publicado: (2017)

Myocarditis mimicking acute myocardial infarction
por: van Nierop, J., et al.
Publicado: (2015)

Opportunistic screening for atrial fibrillation with a single lead device in geriatric patients
por: Zwart, Lennaert AR, et al.
Publicado: (2020)

Screening for Atrial Fibrillation in Sub-Saharan Africa: A Health Economic Evaluation to Assess the Feasibility in Nigeria
por: Jacobs, M. S., et al.
Publicado: (2021)

Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
por: de Jong, Lisa A., et al.
Publicado: (2019)

Correction: Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
por: de Jong, Lisa A., et al.
Publicado: (2022)

Mobile health: solution or a threat?
por: Tieleman, R. G., et al.
Publicado: (2018)

Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands
por: Stevanović, Jelena, et al.
Publicado: (2014)

Inappropriate non-vitamin K antagonist oral anticoagulants prescriptions: be cautious with dose reductions
por: Jacobs, M. S., et al.
Publicado: (2019)

Time of onset of atrial fibrillation and atrial fibrillation progression data from the RACE V study
por: van de Lande, Martijn E, et al.
Publicado: (2023)

Optimal antithrombotic treatment of patients with atrial fibrillation undergoing percutaneous coronary intervention: triple therapy is too much!
por: Jacobs, M. S., et al.
Publicado: (2018)

Screening over 100 000 patients in 39 general practices in the Netherlands for anticoagulation underprescription in atrial fibrillation: a descriptive, cross-sectional study
por: Voorhout, Leonard, et al.
Publicado: (2023)

Design and rationale of DUTCH-AF: a prospective nationwide registry programme and observational study on long-term oral antithrombotic treatment in patients with atrial fibrillation
por: Chu, Gordon, et al.
Publicado: (2020)

Building Blocks Towards a Proportionate Chemicals Policy With a Focus on the Netherlands
por: Helsloot, Ira, et al.
Publicado: (2022)

A Short Critique on the Stance of the Netherlands Food and Consumer Product Safety Authority on Melamine Polymer Formaldehyde Exposures
por: Hanekamp, Jaap C.
Publicado: (2021)

Number of comorbidities is associated with symptom severity and arrhythmia progression in paroxysmal atrial fibrillation - Data from the RACE V study
por: Van De Lande, M E, et al.
Publicado: (2023)

The Cost-Effectiveness of Hepatitis C Virus Screening Strategies among Recently Arrived Migrants in the Netherlands
por: Al Khayat, Mohamed N.M.T., et al.
Publicado: (2020)

Cost-effectiveness of screening smokers and ex-smokers for lung cancer in the Netherlands in different age groups
por: Al Khayat, Mohamed N. M. T., et al.
Publicado: (2022)

Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and the Netherlands: insights from the ETNA-AF-Europe study
por: de Vries, T. A. C., et al.
Publicado: (2021)

Contemporary management of patients with atrial fibrillation in the Netherlands and Belgium: a report from the EORP-AF long-term general registry
por: Erküner, Ö., et al.
Publicado: (2021)

Brady- and tachyarrhythmias detected by continuous rhythm monitoring in paroxysmal atrial fibrillation
por: Frausing, Maria Hee Jung Park, et al.
Publicado: (2023)

Prevalence and determinants of atrial fibrillation progression in paroxysmal atrial fibrillation
por: Nguyen, Bao-Oanh, et al.
Publicado: (2023)

New-onset atrial fibrillation during critical illness: another piece of the puzzle
por: Seelig, Jaap, et al.
Publicado: (2022)

The Need for a Data Ecosystem for Youth Mental Health in The Netherlands
por: Kleinjan, Marloes, et al.
Publicado: (2022)

Acute heart failure and iron deficiency: a prospective, multicentre, observational study
por: van Dalen, Dirk H., et al.
Publicado: (2021)

Yield of screening for atrial fibrillation in primary care with a hand-held, single-lead electrocardiogram device during influenza vaccination
por: Kaasenbrood, Femke, et al.
Publicado: (2016)

Emergency department presentations because of atrial fibrillation: too many, too soon
por: Pisters, R., et al.
Publicado: (2021)

The management of cardiovascular disease in the Netherlands: analysis of different programmes
por: Cramm, Jane M., et al.
Publicado: (2013)

Optimal long-term antithrombotic management of atrial fibrillation: life cycle management
por: Pisters, R., et al.
Publicado: (2018)

Brady- and tachyarrhythmias in paroxysmal atrial fibrillation: results from long-term continuous electrocardiographic monitoring in RACE V
por: Park Frausing, M H J, et al.
Publicado: (2023)

Paradigm shifts in pathophysiology and management of atrial fibrillation—a tale of the RACE trials in the Netherlands
por: Crijns, H. J. G. M., et al.
Publicado: (2020)

Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trial
por: Nguyen, Bao Oanh, et al.
Publicado: (2021)

Higher Levels of Harsh Parenting During the COVID-19 Lockdown in the Netherlands
por: Sari, Novika Purnama, et al.
Publicado: (2022)

Who's who in the Netherlands, 1962/1963
por: Taylor, Stephen S, et al.
Publicado: (1962)

Time Trends in Patient Characteristics of New Rivaroxaban Users with Atrial Fibrillation in Germany and the Netherlands
por: Voss, Annemarie, et al.
Publicado: (2023)

Effectiveness of the Leptospira Hardjo Control Programme and Detection of New Infections in Dairy Cattle in The Netherlands
por: van den Brink, Katrien M. J. A., et al.
Publicado: (2023)

Opportunistic screening for atrial fibrillation using a photoplethysmography technique in geriatric patients, a preliminary analysis of the Dutch-GERAF Study
por: Zwart, L A R, et al.
Publicado: (2023)

Ruling out acute coronary syndrome in primary care with a clinical decision rule and a capillary, high-sensitive troponin I point of care test: study protocol of a diagnostic RCT in the Netherlands (POB HELP)
por: van den Bulk, Simone, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p3qimusu1vqrsrhc4bgv9ldpfp